The following information was compiled in August 2024 and is subject to change as new research is conducted and as new information becomes available:

Description: AB-CHMINACA is a novel synthetic cannabinoid with structural similarity to MMB-CHMINACA, ADB-CHMINACA, and other synthetic cannabinoids. AB-CHMINACA was first identified and reported to the European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA) in 2014 and was continuously reported until 2017.1 AB-CHMINACA has reemerged and was detected in April 2024 by our laboratory with confirmation via standard reference material.

Sample Source: Georgia Poison Center, Emory University, & Fulton County Jail (Atlanta, GA)

Sample Appearance: Paper samples & toxicology samples

Pharmacology: AB-CHMINACA is an active and potent CB1 receptor agonist (EC50 = 7.4 nM).2

Toxicology: AB-CHMINACA has been identified in sixteen toxicology cases to date at the CFSRE.

Drug Materials: AB-CHMINACA has been detected in five drug materials to date at the CFSRE.

Demographics / Geographics: Toxicology cases and drug materials both originated from Georgia. AB-CHMINACA was found alongside other synthetic cannabinoids (e.g., MDMB-4en-PINACA).

Legal Status: AB-CHMINACA is a Schedule I drug in the United States (21 CFR 1308).

Class: Cannabinoid
 Appearance: Paper
 Formula: C20H28N4O2
 MW: 356.5  [M+]: 356  [M+H]+: 357.2285
 IUPAC: N-(1-carbamoyl-2-methyl-propyl)-1-(cyclohexylmethyl)indazole-3-carboxamide
 Report Date: August 19, 2024